CatchMe Therapeutics is developing a novel class of drugs targeting epitranscriptomic modifiers
Epitranscriptomic modifications and their respective modifier enzymes affect important RNA processing steps such as splicing, translation and stability. M6A is the most abundant mRNA modification, and its modifying enzymes have been found to play an important role in various cancers, influencing propagation, survival and other processes. CatchMe is initially targeting an M6A “writer” enzyme.
Vladislav Krupalnik, PhD – Co-Inventor
Shay Geula, PhD – Co-Inventor
Yael Tsalenchuck, PhD – CSO